S5 – E01.6 – SurfingMASH Is Back! How Can Consumer Behavior Confound MASH Care?

S5 - E01.6 - SurfingMASH Is Back! How Can Consumer Behavior Confound MASH Care?
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this last segment of Episode 1, the co-hosts explore the complexities surrounding advertising and accessibility of metabolic agents in the US market, with a particular focus on how these factors might influence public engagement and healthcare provider education.

The tone of this segment demonstrates concern that gaps or inaccuracies in consumer information might affect patient treatment in the care pathways, as providers who may not yet be equipped to handle inquiries about newly approved liver treatments deal with issues of proper prescribing and access.

Louise Campbell starts this conversation by reflecting on the challenges and frustrations caused by price and access disparities when DAAs entered the Hepatitis C market. In her UK practice, native Egyptians went back to Egypt to purchase DAAs at £1,000, which meant that the UK care team lost control of patient information. She highlights the importance of educating not just physicians but also allied health professionals who spend more time with patients, to ensure they can have informed discussions about new medications and their management. She proposes exploring education strategies and designing clinical pathways to support the effective introduction of new treatments. She mentions upcoming recommendations for fatty liver in Australia as an example of progress in liver health management.

Roger Green expresses interest in delving into diagnostics challenges, especially considering the rapid uptake of semaglutide and tirzepatide as weight loss drugs offered by telemedicine providers outside the traditional care paradigm. He worries about the potential this model has to leave treaters with inadequate or inaccurate knowledge of their patients, and advocates for a more educated approach by payers to include liver-aware diagnostics in metabolic disease management to better serve patient needs and prevent liver-related complications.

Jörn Schattenberg also advocates for broader, deeper education campaigns while noting that there appear to be few if any interactions between GLP-1s and resmetirom based on clinical trial reports.

This conversation underscores the interconnected challenges of drug marketing, healthcare provider education, and diagnostic practices in the evolving landscape of liver treatment and highlights the need for a multifaceted approach to address these issues effectively.

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.

Sponsoring Partnerships!

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.